• Completed

NCT00083551: UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma

Updated: Sep 27

This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after transplant will be beneficial. Another objective is to find out what kinds of side effects occur with this combination of treatment and how often they occur.

TOTAL THERAPY 2

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy


Sponsor

University of Arkansas


Collaborator

Celgene Corporation

 

ClinicalTrials.gov Identifier: NCT00083551

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

First Posted : May 27, 2004

Click here for details on ClinicalTrials.gov

 

Thalidomide Ara-C BCNU Cisplatin Cytoxan Dexamethasone Doxorubicin Etoposide Filgrastim Recombinant GM-CSF Interferon-alpha-2b Melphalan Vincristine

 

PMID: 16525139

N Engl J Med; March 2006

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

Click here for details

 

Location

United States, Arkansas

Principal Investigator:Bart Barlogie, M.D., Ph.D.UAMS



Posts Archive